IREDA LISTING PRICE NEWS
Phillip Capital sees a 56% downside potential in IREDA shares as best value already priced in
Phillip Capital maintains a sell view on IREDA, citing concerns over earnings growth not keeping pace with loan growth. Despite strong loan growth prospects, the company faces challenges in maintaining return ratios and credit costs.
IREDA shares zoom 9% after PAT jumps 30% YoY in Q1
Shares of IREDA rallied 9% to a fresh 52-week high of Rs 310 on BSE after the company reported a net profit of Rs 384 crore for the quarter ended June 30, 2024, compared to Rs 295 crore in the year-ago period.
IREDA Q1 Results: PAT jumps 30% YoY to Rs 384 crore, revenue surges 32%
IREDA Q1 Results: The state-run NBFC saw a significant increase in loan sanctions, up 387% to Rs 9,210 crore compared to Rs 1,892 crore in the same period last year. Loan disbursements also rose by 68%, reaching Rs 5,326 crore compared to Rs 3,173 crore in the previous year.
Effwa Infra and Research stock debuts with 90% premium over issue price
Effwa Infra Share Price: Effwa Infra and Research's shares debuted on the NSE SME platform with a 90% premium on Friday, opening at Rs 155.8 compared to an issue price of Rs 82. Prior to listing, the company's shares traded at a premium of Rs 74. The IPO, consisting of a fresh equity sale of Rs 43 crore and an Offer for Sale (OFS) of Rs 7.68 crore, garnered strong investor interest, oversubscribing by over 200 times at close.
Ganesh Green Bharat shares list at 90% premium over IPO price
Ganesh Green Bharat Share Price: Ganesh Green Bharat's shares debuted on the NSE SME platform with a 90% premium on Friday, opening at Rs 361 against an issue price of Rs 190. Prior to listing, the company's shares traded at a premium of Rs 170. The IPO, consisting entirely of fresh equity of 65.91 lakh shares, saw exceptional investor interest, oversubscribing 200 times by closing.
Reliance Jio IPO: Listing likely in 2025 at $112 billion valuation, says Jefferies
Investors anticipate the impending Reliance Jio IPO as billionaire Mukesh Ambani remains tight-lipped. The recent telecom tariff hike is seen as a precursor to this long-awaited event. Jefferies, a global investment banking firm, suggests that the high-profile listing could materialize in 2025, valuing Jio at $112 billion.
- Go To Page 1
Bansal Wire share price falls marginally post robust listing. Should you hold or exit?
Bansal Wire Industries debuted with a 39% premium on its issue price, driven by robust investor demand. Post-listing, shares dipped slightly but traded 36% above the IPO price at Rs 349.5. Analysts highlight strong customer diversification and a diverse product portfolio, mitigating revenue risks across sectors.
Emcure Pharma shares jump over 4% post listing. Should you buy, sell or hold?
Pune-based Emcure Pharmaceuticals listed at Rs 1,325, a 31.4% premium on Rs 1,008 IPO price. QIBs subscribed 195.8 times, non-institutional investors 48.3 times. Analysts recommend long-term holding. IPO proceeds target debt and corporate purposes. Offering products in therapeutic areas, Emcure recorded Rs 6,658 crore revenue in FY24 and operates in Europe, Canada.
Emcure Pharma shares debut with 31% premium over issue price
Before listing, the company's shares traded at a Rs 360 premium in the grey market. It raised Rs 582 crore from anchor investors, including HDFC MF, ICICI Pru MF, SBI MF, Abu Dhabi Investment Authority, Goldman Sachs Asset Management, Nomura, and HDFC Life. Analysts are bullish on the IPO for listing gains and long-term growth, citing its strong position in domestic therapeutics and expansion plans in India and exports.
Bansal Wire IPO shares to debut on Wednesday. What GMP signals ahead of listing
Bansal Wire shares will debut on the bourses on Wednesday. Ahead of the listing, the company's shares were trading with a grey market premium of Rs 63. The company proposes to use the funds from the IPO to repay some of its debt, working capital requirements, and other general corporate purposes.
Does NSE's price capping on SME IPOs mean no multibagger returns on Day 1?
As SME IPOs gain traction among investors, regulators are moving to formalise the market with stricter controls. The NSE recently imposed a cap on SME issue listing prices at 90%, independent of grey market trends. This impacted Nephro Care, which despite a 300% pre-listing GMP, debuted at only a 90% premium due to the exchange's price cap.
NSE imposes price control cap of 90% on SME IPOs amid froth concerns
"To standardize the opening price discovery/ equilibrium price across exchanges during special pre-open session for initial public offer (IPO) for the SME platform, it has been decided to put an overall capping up to 90% over the Issue price for SME IPOs," NSE said in a circular.
Vraj Iron and Steel shares list at 16% premium over IPO price
Vraj Iron and Steel's strong listing surge correlates with its exceptional 126.36 times subscription rate, reflecting robust investor confidence. Analysts highlight risks including regional facility concentration and absence of long-term customer contracts, advising cautious consideration amidst the company's promising outlook.
Allied Blenders and Distillers shares see below par listing. Should you hold or exit?
Allied Blenders and Distillers' shares had a positive listing but fell short of expected gains due to lower grey market premiums. They debuted at Rs 320 per share, up 13% from the issue price, below the anticipated 17% gains. Post-listing, continuous decline in stock price dampened investor sentiment.
Allied Blenders and Distillers shares list at 14% premium over issue price
Allied Blenders, post IPO debut, saw a 14% premium. The company holds 8% IMFL market share in India. Revenue grew by 9% and profit after tax by 50%. Facing financial volatility, it expanded the product portfolio with a strong brand presence.
IREDA shares surge nearly 6% after sanctioned loans amount jumped nearly 5 times
Shares of the Indian Renewable Energy Development Agency (IREDA) surged 6% to reach the day’s high of Rs 202 on the BSE. This increase followed the company's announcement of significant year-on-year growth in its sanctioned loans by 382.62% and loan disbursements by 67.61%.
Multibagger debut! Shivalic Power Control shares list at 211% premium over IPO price
The IPO, which was completely a fresh equity sale of 64.32 lakh shares, was subscribed over 250 times at close, driven by strong interest from retail and non-institutional investors.
Visaman Global Sales shares list at a 5% premium over IPO price
Visaman Global Sales debuted on the NSE SME platform with a 4.88% premium on Monday, opening at Rs 45.10 compared to its issue price of Rs 43. Prior to its listing, the company's shares traded at a premium of Rs 13 in the unlisted market. The IPO, consisting entirely of fresh equity comprising 37.32 lakh shares, was oversubscribed by over 42 times.
Multibagger Debut! Medicamen Organics stock debuts with 305% premium on NSE SME platform
Medicamen Organics, a pharmaceutical company, saw a successful listing on the NSE SME platform with a substantial premium. The company focuses on international markets, diverse pharmaceutical dosage forms, and global expansion strategies, reflecting its growth potential and market adaptability.
Stanley Lifestyles shares list at 35% premium over issue price
Stanley Lifestyles' successful IPO debut and premium listing reflect its position as a leading luxury furniture brand. With strong financial backing and strategic partnerships, the company is poised for significant growth in the upscale furniture market.
Akme Fintrade shares see a moderate listing. Should you exit?
Akme Fintrade, a rural and semi-urban-focused NBFC, had a moderate listing on Wednesday. Its shares opened at Rs 127, marking a 5.83% increase from its issue price of Rs 120. This performance contrasts sharply with the earlier excitement indicated by a higher pre-listing GMP. Despite receiving decent oversubscription, analysts noted that Akme Fintrade's cautious listing suggests investor restraint.
GEM Enviro Management shares list at 90% premium on BSE SME platform
Prior to its listing, GEM Enviro Management shares were trading with a Grey Market Premium (GMP) of Rs 70 in the unlisted market. The IPO, comprising entirely of a fresh equity issue of 59.9 lakh shares, was oversubscribed by over 200 times at closure, primarily fueled by robust interest from non-institutional investors. Proceeds from the public offer will be allocated towards funding working capital requirements and general corporate purposes.
Akme Fintrade shares list at 6% premium over issue price
Ahead of the listing, the company's shares were trading in the unlisted market with a Grey Market Premium (GMP) of Rs 18. The IPO, consisting solely of a fresh equity sale of 1.1 crore shares, was oversubscribed by 53 times at closure. Due to intense competition in the domestic NBFC sector, analysts expressed caution regarding the IPO.
Ixigo share price jumps over 13% after listing at healthy premium
Shares of Le Travenues Technologies' travel platform Ixigo surged 13% from Rs 135 to Rs 152.21 on BSE after a strong listing. The company's AI-powered operations provide a competitive edge in the online travel sector.
Ixigo shares debut at 48.5% premium over issue price
Ixigo IPO was booked nearly 98.34 times at close on strong interest from non-institutional and institutional buyers. Ahead of the listing, the company's shares traded with a premium of Rs 30 in the unlisted market.
Kronox Lab Sciences shares list at 21% premium over issue price
Kronox Lab Sciences boasts a strong position in the specialty fine chemicals sector. Their diverse product portfolio caters to various industries, creating long-term growth potential. High entry and exit barriers due to stringent manufacturing processes offer them a competitive edge.
Unlisted shares offer terrific returns, but also carry very high risks; should you invest?
In the past decade, many Indians have embraced the equity culture and started investing in stocks and equity mutual funds. Some analysts feel that retail investors should put money in unlisted shares if they want outsized returns. Other financial advisers say retail investors should not dabble in unlisted shares for the simple reason that the risk they entail is not worth the rewards they offer.
Stock Radar: Multibagger returns in less than 1 year! This green NBFC player is poised for continued growth
IREDA has rallied by about 190% since its November 2023 listing. After reaching 215 in February, the momentum in the stock fizzled out. It continued to drift lower and found support above 120 levels in March. The stock is trading well above most of the crucial moving averages such as 5,10,30,50 and 100-DMA on the daily charts.
Load More
